Table 2.
Chemotherapy Lines and Agents
| N=167(%) | |
|---|---|
| Systemic Chemotherapy and | 93(56) |
| HAI | |
| HAI Agents | |
| FUDR monotherapy | 93(100) |
| FUDR/Mitomycin | 35(38) |
| Gemcitabine | 3(3) |
| Systemic Agents | |
| Gemcitabine regimen | 80(86) |
| Irinotecan regimen | 62(67) |
| 5-Fluoruracil regimen | 50(54) |
| Systemic Chemotherapy Only | 74(44) |
| First Line Regimen | |
| Gemcitabine-based | 58(78) |
| Gemcitabine Monotherapy | 18(24) |
| Gemcitabine with second agent* | 40(76) |
| Other Agents* | 16(22) |
| Second Line Regimen | 34(46) |
| 5-Fluoruracil-based | 22(65) |
| Third Line Regimen | 7(9) |
*
A variety of systemic chemotherapy regimens were used: gemcitabine monotherapy, gemcitabine/cisplatin, gemcitabine/cisplatin/sorafenib, gemcitabine/cisplatin/irinotecan, gemcitabine/oxaliplatin, gemcitabine/capecitabine, gemcitabine/erlotinib, gemcitabine/irinotecan, gemcitabine/carboplatin/taxol, 5-fluoruracil, 5-fluoruracil/irinotecan, 5-fluoruracil/oxaliplatin, other systemic agents (GX-8951S, platinum based regimens, taxol based regimens)